Physician profile
Beth A Cohen
NPI 1902901135
$11,467.21
in general payments reported to CMS, 2019-2025
60 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,017 · 2020: $853 · 2021: $1,819 · 2022: $2,973 · 2023: $2,634 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,805 · Education: $1.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,804.82 |
| Education | $1.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,412.60 | 2019-2023 | Tysabri, Vumerity, Tysabri |
| Livanova USA, INC. | $1,007.63 | 2019-2022 | |
| Abbvie INC. | $966.17 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Novartis Pharmaceuticals Corporation | $885.23 | 2019-2023 | |
| Lilly USA, LLC | $520.06 | 2019-2023 | Amyvid, Emgality |
| Supernus Pharmaceuticals, INC. | $471.74 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $412.87 | 2020-2023 | Rytary |
| Lundbeck LLC | $384.51 | 2019-2023 | Vyepti |
| Esperion Therapeutics, INC. | $348.33 | 2021-2023 | Nexletol, Nexlizet |
| Eisai INC. | $339.10 | 2019-2023 | |
| Amgen INC. | $316.07 | 2019-2022 | |
| Ucb, INC. | $303.68 | 2019-2023 | Nayzilam |
| Collegium Pharmaceutical, INC. | $235.45 | 2019-2023 | Xtampza |
| Janssen Pharmaceuticals, INC | $229.21 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $202.92 | 2019-2022 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.